
- | INmune Bio
XPro1595 significantly improves neurodegeneration in AD trial
INmune Bio, Inc., who developed the drug, noted that the analysis highlighted an approximate two-fold reduction in the neurodegeneration markers visinin-like protein 1 (VILIP-1) and neurofilament light (NFL), as well as an almost three-fold change in contactin-2 and a half-fold change in neurogranin, both proteins associated with synaptic plasticity. These improvements were sustained through the nine-month timepoint (the total length of the study so far).

- | Vaxart
Tackling Covid-19 variants with next-generation vaccines
When SARS-CoV-2 emerged on to the global stage in early 2020, many pharma groups leapt into action. After receiving the genetic code of the emerging coronavirus from researchers in Australia and China in mid-January, these companies signed deals and started to apply existing technology – often used for previous coronaviruses like SARS and MERS – to develop vaccines targeting the S protein used by SARS-CoV-2 to infect human cells.

- | Clover Biopharma
In the pipeline: What the next wave of COVID-19 vaccines could look like
We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials – and how they could offer a point of difference to authorized vaccines.

- | Acepodia
Acepodia’s Approach To ACC & CAR Manufacturing Scalability
Acepodia CEO, President, & Co-founder Dr. Sony Hsiao and Dr. Mark Gilbert, VP of R&D, join Erin Harris and Matt Pillar for a discussion on the company’s approach to dramatically reducing the cost of cell therapy development, manufacturing, and administration via its oNK, CAR, and ACC candidates.

- | Cue Biopharma
Rogue antibodies could be driving severe COVID-19
Finding a rock-solid connection can be tough, because it’s difficult to show whether the infections are the cause of autoimmune disorders or whether they crop up in the body for another reason, says Anish Suri, president of Cue Biopharma, a company in Cambridge, Massachusetts, that is researching therapies to counter autoimmunity.

- | Clene Nanomedicine
Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease
Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $31.9 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases.

- | Immuneering
Disease-cancelling drugs: Immuneering raises $62m in Series B round
Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be used to support the company’s portfolio – particularly its lead candidate – as well as its computational biology services business.
- | Aridis Pharmaceuticals
JPM: Aridis CEO Truong on why the pandemic hasn’t bolstered antibiotics R&D and what needs to change
With its pipeline of bacteria-fighting monoclonal antibodies, Aridis is working to tackle the first two problems: injecting innovation into the space and testing its programs in a way that show they’re better than the incumbents rather than simply not worse.